Bill Barberich

Bill Barberich has extensive work experience with Pfizer. From 2016 to the present (ongoing), they have held the role of Vice President of Operations for Global Sterile Injectables. In this position, they provide leadership for Pfizer's global network of sterile injectable manufacturing sites, with a team of over 14,000 colleagues. Bill is responsible for overseeing the production of over 2 billion sterile doses annually and managing an operating budget of approximately $7 billion.

Prior to their current role, from 2016 to 2018, Bill Barberich served as Vice President of Operations for the Rx Solid Oral Dose product. In this capacity, they led the Solid Oral Dose Pharmaceutical network, which included facilities in various countries and supplied over $20 billion in revenue, primarily driven by the Lipitor, Lyrica, and Eliquis brands.

From 2013 to 2016, Barberich was the Vice President of Operations for Consumer Healthcare at Pfizer. In this role, they provided leadership for the global network of manufacturing sites, producing key brands such as Advil, Centrum, Emergen-C, Nexium, and Thermacare. This network supported $3.5 billion in revenue.

Overall, Barberich's work experience with Pfizer demonstrates their expertise in leading major manufacturing operations across multiple product categories and geographic locations, playing crucial roles in the success of the company.

Bill Barberich received a Bachelor of Science degree in Chemistry from SUNY Geneseo in 1985. Bill then went on to earn another Bachelor of Science degree, this time in Chemical Engineering, from Columbia Engineering in 1987. Bill later pursued a Master of Science degree in Chemical Engineering from Columbia University, which they completed in 1990.